• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Alpine Immune Sciences Inc. (Amendment)

    2/14/24 4:43:28 PM ET
    $ALPN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALPN alert in real time by email
    SC 13G/A 1 d783272dsc13ga.htm SC 13G/A SC 13G/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1

    (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2

    (Amendment No. 3)

     

     

    Alpine Immune Sciences, Inc.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    02083G100

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP NO. 02083G100   13G   Page 2 of 10 Pages

     

     1   

     NAMES OF REPORTING PERSONS

     

     Omega Fund VI, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☒(1)

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Cayman Islands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

     0

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     0.0%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     PN

     

    (1)

    This Schedule 13G is filed by Omega Fund VI, L.P. (“Omega Fund”), Omega Fund VI GP, L.P. (“Omega GP”), Omega Fund VI GP Manager, Ltd. (“Omega Ltd”), Claudio Nessi (“Nessi”), Otello Stampacchia (“Stampacchia”), and Anne-Mari Paster (“Paster”) (together, the “Reporting Persons”). Omega Ltd serves as the general partner of Omega GP, which serves as the general partner of Omega Fund; and each of Omega Ltd and Omega GP may be deemed to own beneficially the shares held by Omega Fund. Nessi, Stampacchia, and Paster are the directors of Omega Ltd and may be deemed to beneficially own the shares held by Omega Fund. The Reporting Persons may be deemed a “group” for purposes of Section 13 of the Exchange Act and expressly disclaim status as a “group” for purposes of this Schedule 13G.


    CUSIP NO. 02083G100   13G   Page 3 of 10 Pages

     

     1   

     NAMES OF REPORTING PERSONS

     

     Omega Fund VI GP, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☒(1)

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Cayman Islands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

     0

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     0.0%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     PN

     

    (1)

    This Schedule 13G is filed by Omega Fund VI, L.P. (“Omega Fund”), Omega Fund VI GP, L.P. (“Omega GP”), Omega Fund VI GP Manager, Ltd. (“Omega Ltd”), Claudio Nessi (“Nessi”), Otello Stampacchia (“Stampacchia”), and Anne-Mari Paster (“Paster”) (together, the “Reporting Persons”). Omega Ltd serves as the general partner of Omega GP, which serves as the general partner of Omega Fund; and each of Omega Ltd and Omega GP may be deemed to own beneficially the shares held by Omega Fund. Nessi, Stampacchia, and Paster are the directors of Omega Ltd and may be deemed to beneficially own the shares held by Omega Fund. The Reporting Persons may be deemed a “group” for purposes of Section 13 of the Exchange Act and expressly disclaim status as a “group” for purposes of this Schedule 13G.


    CUSIP NO. 02083G100   13G   Page 4 of 10 Pages

     

     1   

     NAMES OF REPORTING PERSONS

     

     Omega Fund VI GP Manager, Ltd.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☒(1)

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Cayman Islands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

     0

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     0.0%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO

     

    (1)

    This Schedule 13G is filed by Omega Fund VI, L.P. (“Omega Fund”), Omega Fund VI GP, L.P. (“Omega GP”), Omega Fund VI GP Manager, Ltd. (“Omega Ltd”), Claudio Nessi (“Nessi”), Otello Stampacchia (“Stampacchia”), and Anne-Mari Paster (“Paster”) (together, the “Reporting Persons”). Omega Ltd serves as the general partner of Omega GP, which serves as the general partner of Omega Fund; and each of Omega Ltd and Omega GP may be deemed to own beneficially the shares held by Omega Fund. Nessi, Stampacchia, and Paster are the directors of Omega Ltd and may be deemed to beneficially own the shares held by Omega Fund. The Reporting Persons may be deemed a “group” for purposes of Section 13 of the Exchange Act and expressly disclaim status as a “group” for purposes of this Schedule 13G.


    CUSIP NO. 02083G100   13G   Page 5 of 10 Pages

     

     1   

     NAMES OF REPORTING PERSONS

     

     Claudio Nessi

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☒(1)

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Switzerland

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

     0

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     0.0%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     IN

     

    (1)

    This Schedule 13G is filed by Omega Fund VI, L.P. (“Omega Fund”), Omega Fund VI GP, L.P. (“Omega GP”), Omega Fund VI GP Manager, Ltd. (“Omega Ltd”), Claudio Nessi (“Nessi”), Otello Stampacchia (“Stampacchia”), and Anne-Mari Paster (“Paster”) (together, the “Reporting Persons”). Omega Ltd serves as the general partner of Omega GP, which serves as the general partner of Omega Fund; and each of Omega Ltd and Omega GP may be deemed to own beneficially the shares held by Omega Fund. Nessi, Stampacchia, and Paster are the directors of Omega Ltd and may be deemed to beneficially own the shares held by Omega Fund. The Reporting Persons may be deemed a “group” for purposes of Section 13 of the Exchange Act and expressly disclaim status as a “group” for purposes of this Schedule 13G.


    CUSIP NO. 02083G100   13G   Page 6 of 10 Pages

     

     1   

     NAMES OF REPORTING PERSONS

     

     Otello Stampacchia

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☒(1)

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Italy

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

     0

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     0.0%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     IN

     

    (1)

    This Schedule 13G is filed by Omega Fund VI, L.P. (“Omega Fund”), Omega Fund VI GP, L.P. (“Omega GP”), Omega Fund VI GP Manager, Ltd. (“Omega Ltd”), Claudio Nessi (“Nessi”), Otello Stampacchia (“Stampacchia”), and Anne-Mari Paster (“Paster”) (together, the “Reporting Persons”). Omega Ltd serves as the general partner of Omega GP, which serves as the general partner of Omega Fund; and each of Omega Ltd and Omega GP may be deemed to own beneficially the shares held by Omega Fund. Nessi, Stampacchia, and Paster are the directors of Omega Ltd and may be deemed to beneficially own the shares held by Omega Fund. The Reporting Persons may be deemed a “group” for purposes of Section 13 of the Exchange Act and expressly disclaim status as a “group” for purposes of this Schedule 13G.


    CUSIP NO. 02083G100   13G   Page 7 of 10 Pages

     

     1   

     NAMES OF REPORTING PERSONS

     

     Anne-Mari Paster

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States of America

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

     0

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     0.0%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     IN

     

    (1)

    This Schedule 13G is filed by Omega Fund VI, L.P. (“Omega Fund”), Omega Fund VI GP, L.P. (“Omega GP”), Omega Fund VI GP Manager, Ltd. (“Omega Ltd”), Claudio Nessi (“Nessi”), Otello Stampacchia (“Stampacchia”), and Anne-Mari Paster (“Paster”) (together, the “Reporting Persons”). Omega Ltd serves as the general partner of Omega GP, which serves as the general partner of Omega Fund; and each of Omega Ltd and Omega GP may be deemed to own beneficially the shares held by Omega Fund. Nessi, Stampacchia, and Paster are the directors of Omega Ltd and may be deemed to beneficially own the shares held by Omega Fund. The Reporting Persons may be deemed a “group” for purposes of Section 13 of the Exchange Act and expressly disclaim status as a “group” for purposes of this Schedule 13G.


    Introductory Note: This statement on Schedule 13G is filed on behalf of the Reporting Persons, in respect of shares of Common Stock (“Common Stock”), of Alpine Immune Science, Inc. (the “Issuer”).

    Item 1(a) Name of Issuer:

    Alpine Immune Sciences, Inc. (the “Issuer”)

    Item 1(b) Address of Issuer’s principal executive offices:

    Alpine Immune Sciences, Inc.

    188 East Blaine Street, Suite 200

    Seattle, WA 98102

    Items 2(a) Name of Reporting Persons filing:

    Omega Fund VI, L.P. (“Omega Fund”)

    Omega Fund VI GP, L.P. (“Omega GP”)

    Omega Fund VI GP Manager, Ltd. (“Omega Ltd”)

    Claudio Nessi (“Nessi”)

    Otello Stampacchia (“Stampacchia”)

    Anne-Mari Paster (“Paster”)

    Item 2(b) Address or principal business office or, if none, residence:

    The address of the principal business office of Omega Fund, Omega GP, Omega Ltd, Nessi, Stampacchia, and Paster, is c/o Omega Fund Management, LLC, 888 Boylston Street, Suite 1111, Boston, MA 02199.

    Item 2(c) Citizenship:

     

    Name

       Citizenship or Place of Organization
    Omega Fund    Cayman Islands
    Omega GP    Cayman Islands
    Omega Ltd    Cayman Islands
    Nessi    Switzerland
    Stampacchia    Italy
    Paster    United States of America

    Item 2(d) Title of class of securities:

    Common Stock

    Item 2(e) CUSIP No.:

    02083G100

    Item 3 If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filings is a:

    Not applicable.

    Item 4 Ownership

    The following information with respect to the ownership of Common Stock of the Issuer by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2023.


    Reporting Persons    Shares of
    Common
    Stock Held
    Directly
         Sole
    Voting
    Power
         Shared
    Voting
    Power
         Sole
    Dispositive
    Power
         Shared
    Dispositive
    Power
         Beneficial
    Ownership
         Percentage
    of Class
     

    Omega Fund(1)(2)

         0        0        0        0        0        0        0.0 % 

    Omega GP(1)(2)

         0        0        0        0        0        0        0.0 % 

    Omega Ltd(1)(2)

         0        0        0        0        0        0        0.0 % 

    Nessi(1)(2)

         0        0        0        0        0        0        0.0 % 

    Stampacchia(1)(2)

         0        0        0        0        0        0        0.0 % 

    Paster(1)(2)

         0        0        0        0        0        0        0.0 % 

     

    (1)

    As of December 31, 2023, each of the Reporting Persons no longer may be deemed to beneficially own any shares of the Issuer’s Common Stock. 

    (2)

    The Reporting Persons may be deemed a “group” for purposes of Section 13 of the Exchange Act and expressly disclaim status as a “group” for purposes of this Schedule 13G.

    Item 5 Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owners of more than five percent of the class of securities, check the following: ☒

    Item 6 Ownership of More than Five Percent on Behalf of Another Person

    Not applicable.

    Item 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not applicable.

    Item 8 Identification and Classification of Members of the Group

    Not applicable.

    Item 9 Notice of Dissolution of Group

    Not applicable.

    Item 10 Certifications

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 14, 2024

     

    OMEGA FUND VI, L.P.
    BY:   Omega Fund VI GP, L.P.
    ITS:   GENERAL PARTNER
    BY:   Omega Fund VI GP Manager, Ltd.
    ITS:   GENERAL PARTNER
    By:  

    /s/ Otello Stampacchia

      Director
    OMEGA FUND VI GP, L.P.
    BY:   Omega Fund VI GP Manager, Ltd.
    ITS:   GENERAL PARTNER
    By:  

    /s/ Otello Stampacchia

      Director
    OMEGA FUND VI GP MANAGER, LTD.
    By:  

    /s/ Otello Stampacchia

      Director

    /s/ * Otello Stampacchia, as Attorney-in-Fact

    Claudio Nessi

    /s/ Otello Stampacchia

    Otello Stampacchia

    /s/ * Otello Stampacchia, as Attorney-in-Fact

    Anne-Mari Paster
    Get the next $ALPN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ALPN

    DatePrice TargetRatingAnalyst
    4/9/2024$55.00Buy
    Guggenheim
    2/15/2024$44.00Outperform
    Wolfe Research
    10/18/2023$18.00Buy
    Berenberg
    10/17/2023$18.00Buy
    Berenberg
    10/5/2023$19.00Outperform
    RBC Capital Mkts
    6/26/2023$14.00Outperform
    Oppenheimer
    1/19/2023$17.00Overweight
    Morgan Stanley
    11/21/2022$15.00Outperform
    SVB Leerink
    More analyst ratings

    $ALPN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Alpine Immune Sciences with a new price target

      Guggenheim initiated coverage of Alpine Immune Sciences with a rating of Buy and set a new price target of $55.00

      4/9/24 7:38:17 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wolfe Research initiated coverage on Alpine Immune Sciences with a new price target

      Wolfe Research initiated coverage of Alpine Immune Sciences with a rating of Outperform and set a new price target of $44.00

      2/15/24 6:19:18 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Berenberg initiated coverage on Alpine Immune Sciences with a new price target

      Berenberg initiated coverage of Alpine Immune Sciences with a rating of Buy and set a new price target of $18.00

      10/18/23 7:51:16 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALPN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Frazier Life Sciences Appoints Biotech Innovators Mitchell H. Gold and Stanford L. Peng as Venture Partners

      Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointments of Mitchell H. Gold, M.D., and Stanford L. Peng, M.D., Ph.D., as Venture Partners. "We believe Mitch and Stanford bring exceptional leadership and experience that will elevate our ability to create and nurture breakthrough biopharmaceutical companies," said Jamie Topper, M.D., Ph.D., Managing Partner at FLS. "Mitch's history of building transformative companies, his relentless pursuit of scientific excellence and his proven ability to identify transformative scientific and investment opportunities make him a valuable addition to our team. Similarly, Stanford's p

      1/9/25 8:00:00 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Attovia Therapeutics Announces Election of Mitchell Gold and Angie You to Board of Directors

      FREMONT, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics today announced the election of Mitchell H. Gold, M.D., and Angie You, Ph.D., as independent members of its Board of Directors. Drs. Gold and You are seasoned biotech executives and experienced board members who bring decades of industry leadership experience, including early- and late-stage therapeutic development and commercialization. "I am delighted to welcome Mitch and Angie to the team. They are industry leaders with a proven track record of success in building both public and private biopharma companies. As Attovia looks toward our next stage of growth and drives our mission of bringing forward first-in-c

      7/9/24 7:30:00 AM ET
      $ALPN
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alpine Immune Sciences Reports First Quarter 2024 Financial Results

      Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2024. On April 10, 2024, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Alpine announced that the companies had entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share in cash. The transaction was unanimously approved by both the Vertex and Alpine Boards of Directors and is anticipated to close in the second quarter of 2024. First Quarter 2024 Financial Results Cash Position and Runway: As of March

      5/9/24 4:00:00 PM ET
      $ALPN
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALPN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Decheng Capital Global Healthcare Fund (Master), Lp bought $4,687,500 worth of shares (375,000 units at $12.50) (SEC Form 4)

      4 - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Issuer)

      11/14/23 5:36:42 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALPN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Peetz Christopher returned 1,900 shares to the company (SEC Form 4)

      4 - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Issuer)

      5/20/24 8:14:39 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Hernday Natasha

      4 - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Issuer)

      5/20/24 8:13:47 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Drappa Jorn

      4 - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Issuer)

      5/20/24 8:12:51 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALPN
    SEC Filings

    See more
    • SEC Form 15-12G filed by Alpine Immune Sciences Inc.

      15-12G - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Filer)

      5/30/24 9:12:26 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Alpine Immune Sciences Inc.

      EFFECT - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Filer)

      5/24/24 12:15:07 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Alpine Immune Sciences Inc.

      EFFECT - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Filer)

      5/24/24 12:15:33 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALPN
    Leadership Updates

    Live Leadership Updates

    See more
    • Frazier Life Sciences Appoints Biotech Innovators Mitchell H. Gold and Stanford L. Peng as Venture Partners

      Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointments of Mitchell H. Gold, M.D., and Stanford L. Peng, M.D., Ph.D., as Venture Partners. "We believe Mitch and Stanford bring exceptional leadership and experience that will elevate our ability to create and nurture breakthrough biopharmaceutical companies," said Jamie Topper, M.D., Ph.D., Managing Partner at FLS. "Mitch's history of building transformative companies, his relentless pursuit of scientific excellence and his proven ability to identify transformative scientific and investment opportunities make him a valuable addition to our team. Similarly, Stanford's p

      1/9/25 8:00:00 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alpine Immune Sciences Announces Appointment of Wolfgang Dummer, M.D., Ph.D., as Chief Medical Officer and Grant under Nasdaq Listing Rule 5635(c)

      Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the appointment of Wolfgang Dummer, M.D., Ph.D., to Chief Medical Officer effective October 2, 2023. He succeeds Andrew Sandler, M.D., who will transition responsibilities to Dr. Dummer through the remainder of the year. "Wolfgang is a highly accomplished drug developer with deep expertise in rare disease, immunology, and immunotherapy. His experience working across all phases of clinical development through regulatory approval will be important as we continue to advance our pipeline of new therapie

      10/4/23 8:00:00 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alpine Immune Sciences Announces Appointment of M. Christina Yi as Chief Technology Officer and Grant under Nasdaq Listing Rule 5635(c)

      Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the appointment of M. Christina Yi to Chief Technology Officer effective August 21, 2023. Ms. Yi has more than 25 years of biopharmaceuticals leadership experience, including manufacturing, quality, and supply chain. She succeeds Wayne Gombotz, Ph.D., who will retire in August. "Christina is an accomplished industry leader and will be a key addition to our executive team as we prepare for a broad development plan for povetacicept. Her expertise and leadership will be important to Alpine as we contin

      8/22/23 4:30:00 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALPN
    Financials

    Live finance-specific insights

    See more
    • Vertex Enters Into Agreement to Acquire Alpine Immune Sciences

      - Alpine is a clinical stage biotechnology company focused on discovering and developing innovative, protein-based immunotherapies - - Alpine's lead product, povetacicept, demonstrated best-in-class potential in patients with IgA nephropathy (IgAN); Phase 3 to initiate in H2 2024 - - Povetacicept holds promise as a pipeline-in-a-product, with clinical studies in additional serious diseases underway - - Alpine's protein engineering and immunotherapy expertise augments Vertex's toolbox and capabilities - - Vertex to host investor call today, April 10, at 4:30 pm ET - Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a biotechnology com

      4/10/24 4:01:00 PM ET
      $ALPN
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alpine Immune Sciences to Report Fourth Quarter and Full Year 2023 Financial Results

      Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the Company will release fourth quarter and full year 2023 financial results on Monday, March 18, 2024, after the close of market. The Company will host a corresponding conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on the same day. Conference Call and Webcast Information The link to the webcast will be available in the investor relations section of the Company's website at https://ir.alpineimmunesciences.com/events and a replay will be available on the Company's website for 90 days

      3/7/24 4:30:00 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alpine Immune Sciences Presents Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late-Breaking Poster Session at the American Society of Nephrology Kidney Week 2023

      -- Low-dose povetacicept (80 mg administered once every four weeks) was well tolerated during subcutaneous administration and reduced UPCR by greater than 50% in IgA nephropathy -- -- Higher dose povetacicept (240 mg) administered once every four weeks currently being explored -- -- Based on this data Alpine will now seek to begin a pivotal phase 3 IgAN study in the second half of 2024 -- -- Company to host virtual investor call and webcast today at 4:30 pm ET with James Tumlin, M.D. and Jonathan Barratt, Ph.D., FRCP -- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammator

      11/2/23 9:00:00 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALPN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Alpine Immune Sciences Inc. (Amendment)

      SC 13D/A - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Subject)

      5/21/24 4:49:22 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Alpine Immune Sciences Inc. (Amendment)

      SC 13D/A - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Subject)

      5/21/24 10:21:59 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Alpine Immune Sciences Inc. (Amendment)

      SC 13D/A - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Subject)

      4/30/24 4:20:00 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care